Sugi Predict

Sugi Predict / Compounds / SCHEMBL372056

SCHEMBL372056

SCHEMBL372056

CCN(CC)CCOc1cc2ncnc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4(C)C)cc3F)c2cc1OC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 14/20 0.66
▸ EGFR P00533 4/20 0.54
▸ KDR P35968 7/20 0.53
▸ AXL P30530 4/20 0.53
▸ FLT3 P36888 4/20 0.53
▸ KIT P10721 3/20 0.53
▸ HDAC2 Q92769 2/20 0.53
▸ HDAC8 Q9BY41 2/20 0.53
▸ HDAC6 Q9UBN7 2/20 0.53
▸ RET P07949 2/20 0.53
▸ PDGFRB P09619 2/20 0.53
▸ HDAC10 Q969S8 1/20 0.52
▸ HDAC11 Q96DB2 1/20 0.52
▸ FLT1 P17948 2/20 0.50
▸ FLT4 P35916 2/20 0.50
▸ AURKA O14965 2/20 0.50
▸ STK10 O94804 2/20 0.50
▸ RAF1 P04049 2/20 0.50
▸ NTRK1 P04629 2/20 0.50
▸ BRAF P15056 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29693462 1.00 MET (0.66) METEGFRKDRAXLFLT3
SCHEMBL12829177 1.00 MET (0.66) METEGFRKDRAXLFLT3
SCHEMBL29693485 0.96 MET (0.65) METEGFRKDRAXLFLT3
SCHEMBL371795 0.96 MET (0.65) METEGFRKDRAXLFLT3
SCHEMBL29693408 0.90 MET (0.66) METEGFRKDRAXLFLT3
SCHEMBL372002 0.90 MET (0.66) METEGFRKDRAXLFLT3
SCHEMBL29693465 0.90 MET (0.76) METEGFRKDRAXLFLT3
SCHEMBL371698 0.90 MET (0.76) METEGFRKDRAXLFLT3
SCHEMBL12164878 0.89 MET (0.65) METEGFRKDRAXLFLT3
SCHEMBL371904 0.89 MET (0.65) METEGFRKDRAXLFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP claimed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US claimed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20120184523-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-07-19 — — US claimed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 — — EP claimed
US-20110077233-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2011-03-31 — — US claimed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
EP-1673085-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-06-28 — — EP disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885EGFR 124/4885KDR 4/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MET 3/4885EGFR 124/4885KDR 4/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885EGFR 124/4885KDR 4/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885EGFR 124/4885KDR 4/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MET 3/4885EGFR 124/4885KDR 4/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885EGFR 181/4885KDR 5/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MET 3/4885EGFR 124/4885KDR 4/4885
US-20120184523-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885EGFR 181/4885KDR 5/4885
US-20110077233-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885EGFR 181/4885KDR 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.